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We previously reported that hepatitis B virus (HBV) e
antigen (HBeAg) inhibits production of interleukin 6 by
suppressing NF-κB activation. NF-κB is known to be acti-
vated through receptor-interacting serine/threonine protein
kinase 2 (RIPK2), and we examined the mechanisms of in-
terleukin 6 regulation by HBeAg. HBeAg inhibits RIPK2
expression and interacts with RIPK2, which may represent
2 mechanisms through which HBeAg blocks nucleotide-
binding oligomerization domain-containing protein 1
ligand–induced NF-κB activation in HepG2 cells. Our ﬁnd-
ings identiﬁed novel molecular mechanisms whereby
HBeAg modulates intracellular signaling pathways by tar-
geting RIPK2, supporting the concept that HBeAg could
impair both innate and adaptive immune responses to
promote chronic HBV infection.
Hepatitis B virus (HBV) nucleoprotein exists in 2 forms [1, 2].
Nucleocapsid, designated HBV core antigen (HBcAg), is an
intracellular, 21-kDa protein that self-assembles into particles
that encapsidate viral genome and polymerase and is essential
for function and maturation of virion. HBV also secretes a
nonparticle second form of the nucleoprotein, designated
precore or HBV e antigen (HBeAg) [1, 2]. Precore and core
proteins are translated from 2 RNA species that have different
5′ initiation sites. Precore messenger RNA (mRNA) encodes a
hydrophobic signal sequence that directs precore protein to
the endoplasmic reticulum, where it undergoes N- and C-
terminal cleavage within the secretory pathway and is secret-
ed as an 18-kDa monomeric protein [3–5].
Nucleotide-binding oligomerization domain–containing
protein 1 (NOD1) and NOD2 are cytosolic pattern-recognition
receptors involved in the sensing of bacterial peptidoglycan
subcomponents [6]. NOD1 and NOD2 stimulation activates
NF-κB through receptor-interacting serine/threonine protein
kinase 2 (RIPK2; also known as RIP2, RICK, or CARDIAK), a
caspase-recruitment domain-containing kinase. RIPK2 is also
involved in Toll-like receptor (TLR)–signaling pathway and
plays an important role in the production of inﬂammatory cy-
tokines through NF-κB activation [6, 7].
We previously reported that HBeAg inhibits the production
of interleukin 6 (IL-6) through suppression of NF-κB activa-
tion [4]. In the present study, we investigated the molecular
mechanism of HBeAg functions for the requirement of RIPK2
in NF-κB transcriptional regulation.
METHODS
Cell Culture and Plasmids
HepG2, Huh7, HT1080, COS7, and HEK293T cells were used
in the present study. Stable cell lines were obtained as previ-
ously described [4]. Brieﬂy, HepG2, Huh7, and HT1080 were
transfected with pCXN2-HBeAg(+) or pCXN2-HBeAg(−) in
Effectene (Qiagen). After G418 screening, HBeAg-positive and
-negative HepG2/Huh7/HT1080 cell lines were collected for
further analysis [4]. The plasmid pCXN2-HBeAg(+), which
can produce both HBeAg and core peptides, and the plasmid
pCXN2-HBeAg(−), which can produce only core peptides,
were obtained as described previously [4]. pNF-κB–luc, which
expresses luciferase upon promoter activation by NF-κB, was
purchased from Stratagene [4]. pGFP–human RIPK2 (kindly
provided by Prof John C. Reed, Sanford-Burnham Institute for
Medical Research) can express GFP-human RIP2WT [8].
HepG2 cells were transfected with plasmid control–small
hairpin RNA (shRNA) or with RIPK2-shRNA (Santa Cruz).
After puromycin screening, individual colonies were picked
up and examined for expression of endogenous RIPK2, and
clones HepG2-shC and HepG2-shRIPK2-3 were selected for
subsequent studies.
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Luciferase Assays and Treatment of Cells With NOD Ligands
Around 1.0 × 105 HepG2 and Huh7 cells were plated in 6-well
plates (Iwaki Glass, Tokyo, Japan) for 24 hours and transfect-
ed with 0.4 μg of pNF-κB–luc. For luciferase assay of NF-κB
activation, cells were treated for 4 hours with or without
NOD1 ligand (C12-iEDAP, 2.5 μg/mL) and NOD2 ligand
(muramyl dipeptide [MDP], 10 μg/mL) (InvivoGen) at 44
hours after transfection [9]. After 48 hours, cells were lysed
with reporter lysis buffer (Promega), and luciferase activity
was determined as described previously [4].
RNA Extraction, Complementary DNA (cDNA) Synthesis,
Real-Time Polymerase Chain Reaction (PCR) Analysis, and
PCR Array
Total RNA was isolated by RNeasy Mini Kit (Qiagen). A total
of 5 μg of RNA was reverse transcribed using the First Strand
cDNA Synthesis Kit (Qiagen) [4]. Quantitative ampliﬁcation
of cDNA was monitored with SYBR Green by real-time PCR
in a 7300 Real-Time PCR system (Applied Biosystems). Gene
expression proﬁling of 84 TLR-related genes was performed
using RT2 proﬁler PCR arrays (Qiagen) in accordance with
the manufacturer’s instructions [4].
Gene expression was normalized to 2 internal controls
(GAPDH and/or β-actin) to determine the fold-change in gene
expression between the test sample (HBeAg-positive HepG2/
Huh7/HT1080) and the control sample (HBeAg-negative
HepG2/Huh7/HT1080) by the 2−ddCT (comparative cycle
threshold) method [4]. Three sets of real-time PCR arrays were
performed. Some results of HepG2 cells were previously
reported [4].
Coimmunoprecipitation
Cells were cotransfected with 2.5 μg pCXN2-HBeAg(+) or
2.5 μg pCXN2-HBeAg(−), as well as with 2.5 μg pGFP–
human RIPK2, and cell lysates were prepared after 48 hours,
using lysis buffer containing a cocktail of protease inhibitors.
Cell lysates were incubated with anti-GFP rabbit polyclonal
antibody (Santa Cruz) or anti-HBe mouse monoclonal antibody
(Institute of Immunology, Tokyo, Japan) for 3 hours at 4°C,
followed by overnight incubation with protein G–Sepharose
beads (Santa Cruz). Immunoprecipitates were separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
electroblotted onto a nitrocellulose membrane. Immunoblotting
was performed by incubating the membrane for 1 hour with
anti-HBe antibody. Proteins were detected by enhanced chemilu-
minescence (GE Healthcare), using an image analyzer (LAS-
4000, Fuji Film). The membrane was reprobed with a monoclo-
nal antibody to GFP or RIPK2 (Cell Signaling).
Transfection of pGFP–Human RIPK2 and Confocal Microscopy
Formaldehyde (3.7%)–ﬁxed cells were incubated with anti-
HBe antibody and stained with ﬂuorochrome-conjugated sec-
ondary antibody (Alexa Fluor 555 conjugate, Cell Signaling).
Cells were mounted for confocal microscopy (ECLIPSE TE
2000-U, Nikon). Whenever necessary, images were merged
digitally to monitor colocalization. Cotransfection of 0.1 μg
pCXN2-HBeAg(+) or 0.1 μg pCXN2-HBeAg(−) with 0.3 μg
pGFP–human RIPK2 into the cells was performed. After 48
hours, intracellular localization of RIPK2 was visualized by
confocal microscopy.
Enzyme-Linked Immunosorbent Assay (ELISA) for IL-6
Cell culture ﬂuid was analyzed for IL-6 by ELISA (KOMA-
BIOTECH, Seoul, Korea), in accordance with the manufactur-
er’s protocol [4].
Small Interfering RNA (siRNA) Transfection and Wound-
Healing Assay
Control siRNA (siC) and siRNA speciﬁc for RIPK2 (siRIPK2)
were purchased from Thermo Fisher Scientiﬁc. Cells were
transfected with siRNA by electroporation. After 48 hours,
cells were treated with 10 ng/mL tumor necrosis factor α
(TNF-α) (Wako Pure Chemical, Osaka, Japan), while the
wound-healing (ie, scratch) assay was performed using a p-
200 pipette tip to induce RIPK2 [10]. Up to 12 hours after
scratching, the cells were observed by microscopy. Cell migra-
tion was measured using Scion Images (SAS). Migration by
siC-transfected cells was set at 1.
Statistical Analysis
Results are expressed as mean values ± SD. The Student t test
was used to determine statistical signiﬁcance.
RESULTS
HBeAg Downregulates RIPK2 Expression
To explore the effect of HBeAg on TLR-related gene expres-
sion, we generated HepG2, Huh7, and HT1080 cell lines that
stably expressed HBV core region with or without precore
region. HT1080, a primate ﬁbrosarcoma cell line, is useful for
the study of interferon signaling. HBeAg and HBV core–
related antigen (HBcrAg) levels of these cell lines demonstrat-
ed that expression of HBV core region without HBV precore
region did not allow HBeAg secretion by cells (data are cited
elsewhere [4] or not shown). First, we performed real-time
RT-PCR analysis of these cell lines, using focused gene arrays
(Figure 1A). We observed that, in 3 cell lines, 5 genes (RIPK2,
TLR9, TNF, CD180, and IL1A) were downregulated ≥1.3-fold
in HBeAg-positive cells than in HBeAg-negative cells. We chose
to focus our investigation on RIPK2 because HBeAg inhibits
the production of IL-6 through the suppression of NF-κB acti-
vation [4], and NF-κB is known to be activated through
RIPK2 [4]. RIPK2 expression was >100-, 1.41-, and 1.45-fold
lower in HBeAg-positive HepG2, Huh7, and HT1080 cells, re-
spectively, compared with their HBeAg-negative counterparts
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(Figure 1A). Western blot analyses conﬁrmed lower levels of
RIPK2 in HBeAg-positive HepG2 than in HBe-negative HepG2
or parental HepG2 (Figure 1B). The fact that RIPK2 is one of
the targets for the ubiquitin proteasome system and uses a
ubiquitin-dependent mechanism to achieve NF-κB activation
[6] might be a reason for the differences between RIPK2
mRNA and protein expression status. We also observed lower
levels of RIPK2 mRNA expression (0.18-fold) in HepG2.2.15
cells, which secrete complete HBV virion and HBeAg, com-
pared with expression in HepG2 cells (data not shown).
Knockdown of RIPK2 and HBeAg Impairs Hepatic
Cell Migration
It has recently been reported that RIPK2 expression is induced
by TNF-α plus scratch wounding in keratinocytes [10]. There-
fore, we next examined whether RIPK2 affected hepatic
Figure 1. Receptor-interacting serine/threonine protein kinase 2 (RIPK2) expression is downregulated by hepatitis B virus e antigen (HBeAg), and
knockdown of RIPK2 and HBeAg impairs hepatic wound repair. A, Venn diagram representing Toll-like receptor (TLR)–related genes downregulated
≥1.3-fold in HBeAg-positive HepG2/Huh7/HT1080 cells, compared with HBeAg-negative cells. Cellular RNA was extracted and analyzed with focused
array, quantifying 84 genes. Gene expression levels were normalized to actin and GAPDH expression levels. B, HBeAg downregulates RIPK2 expression
in HepG2 cells. Western blot analysis of RIPK2 and tubulin expression in HepG2, HBeAg(+) HepG2, and HBeAg(−) HepG2. C, Experimental protocol of
electroporation of control (siC) and RIPK2 (siRIPK2) small interfering RNA (siRNA) into HepG2 cells. D and E, Real-time polymerase chain reaction (PCR;
D) and Western blot (E) analyses of RIPK2 expression in siC- or siRIPK2-expressing HepG2 cells. RIPK2 messenger RNA (mRNA) levels were normalized
to GAPDH levels. F–H, siC- and siRIPK2-transfected HepG2 cells were scratch wounded and incubated with 10 ng/mL tumor necrosis factor α (TNF-α),
and cell migration was analyzed after 12 hours and quantiﬁed using Scion Image (F). Interleukin 6 (IL-6; G) and interleukin 8 (IL-8; H) mRNA expression
are quantiﬁed by real-time reverse transcription–PCR (RT-PCR) and expressed relative to GAPDH mRNA expression. I, Protocol of wound-healing (ie,
scratch) assay in HBeAg(+) and HBeAg(−) HepG2 cells. TNF-α was used at 10 ng/mL. J, Cell migration was analyzed using Scion Image. K, RIPK2
mRNA expression was quantiﬁed by real-time RT-PCR and expressed relative to GAPDH mRNA expression. Primers speciﬁc for RIPK2 were 5′-AGACAC-
TACTGACATCCAAG-3′ (sense) and 5′-CACAAGTATTTCCGGGTAAG-3′ (antisense), and primers for other genes were as described previously [4]. Data are
mean values ± SD of 3 independent experiments.
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wound healing in the presence of TNF-α in vitro (Figure 1C).
As shown in Figure 1D and 1E, RIPK2 mRNA and protein
expression were efﬁciently decreased in HepG2 cells transfect-
ed with RIPK2 siRNA (siRIPK2), but not control (siC). RIPK2
silencing reduced hepatic wound closure 1.8-fold, which was
associated with a 2-fold decrease in IL-6 production, known
to be an important cytokine for the regeneration of liver [11],
and a 2.3-fold decrease in interleukin 8 production
(Figure 1F–H). Importantly, RIPK2 silencing did not affect
cell viability (data not shown).
Given that HBeAg downregulates RIPK2 expression
(Figure 1A and 1B), we examined whether HBeAg has an
effect on hepatic wound healing in the presence of TNF-α
(Figure 1I). As expected, we observed that both cell migration
Figure 2. The nucleotide-binding oligomerization domain–containing protein 1 (NOD1) ligand C12-iEDAP induces NF-κB activation, knockdown of
receptor-interacting serine/threonine protein kinase 2 (RIPK2) inhibits NOD1 ligand–induced NF-κB activation in HepG2 cells, and hepatitis B virus e
antigen (HBeAg) interacts with RIPK2. A, Real-time reverse transcription–polymerase chain reaction analysis of NOD1 and NOD2 messenger RNA
expression in HepG2. NOD1 and NOD2 expression levels were normalized to GAPDH expression levels. B, NF-κB–driven luciferase activity in HepG2
cells stimulated with the NOD1 ligand C12-iEDAP or the NOD2 ligand muramyl dipeptide (MDP) in HepG2. C, Western blot analysis of RIPK2 and
tubulin expression in HepG2 cells stably transfected with control small hairpin RNA (shRNA; HepG2-shC) or with RIPK2 shRNA (HepG2–shRIPK2-1/2-4)
expressing plasmids. D and E, HepG2-shC (D) and HepG2–shRIPK2-3 (E) cell lines were transiently transfected with pCXN2, pCXN2-HBeAg(+), or
pCXN2-HBeAg(−) plasmids together with pNF-κB–luc. Cells were treated for 4 hours, with or without NOD1 ligand C12-iEDAP (2.5 μg/mL), and lucifer-
ase activity was determined. Primers speciﬁc for NOD1 (sense primer: 5′-ACTACCTCAAGCTGACCTAC-3′; antisense primer: 5′-CTGGTTTACGCTGAGTCTG-
3′), for NOD2 (sense primer: 5′-CCTTGCATGCAGGCAGAAC-3′; antisense primer: 5′-TCTGTTGCCCCAGAATCCC-3′), and for other genes as described
previously were purchased from Sigma [4]. F, HBeAg speciﬁcally colocalizes with RIPK2. COS7 cells were transiently cotransfected with 0.1 μg pCXN2-
HBeAg(+) or pCXN2-HBeAg(−) together with 0.3 μg pGFP–human RIPK2. HBeAg was revealed with anti-HBeAg primary antibody and Alexa-Fluor-548
secondary antibody. G and H, HEK293T cells were transiently transfected with or without GFP-RIPK2 and HBeAg-expressing plasmids. Cellular extracts
were precleared with protein G–Sepharose, and interacting complexes were immunoprecipitated (IP) with either anti-GFP (G) or anti-HBeAg (H) antibod-
ies. Immunocomplexes were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and proteins were visualized by immunoblotting
(WB) with indicated antibodies. Results are representative of 3 independent experiments.
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and RIPK2 mRNA expression were reduced in HBeAg-positive
HepG2 cells, compared with HBeAg-negative cells (1.5-fold
decrease; Figure 1J and 1K). These results suggest that HBeAg
impairs hepatic cell migration–dependent RIPK2 expression.
Among NF-κB–targeting genes, expression of vimentin
mRNAwas impaired in HepG2-shRIP2 and in HBeAg-positive
HepG2 (data not shown), and vimentin might be one of the
candidates for impairment of their migrations [12].
RIPK2 Plays an Important Role in NF-κB Activation Induced by
NOD1 Ligand, and HBeAg Blocks This Pathway
HepG2 cells express NOD1 but not NOD2 at the mRNA level
(Figure 2A). In agreement with this ﬁnding, NF-κB was acti-
vated in HepG2 cells exposed to NOD1 ligand C12-iEDAP
(level of activation, 4.8-fold, compared with untreated control)
but not in those exposed to NOD2 ligand MDP (Figure 2B).
As for Huh7 cells, activation of NF-κB was not detected fol-
lowing exposure to C12-iEDAP or MDP (data not shown).
These results suggest that C12-iEDAP triggered NF-κB activa-
tion through NOD1 in HepG2 cells, which is consistent with
ﬁndings from a previous study [9].
We examined whether knockdown of RIPK2 has an effect
on NOD1-induced NF-κB activation in HepG2 cells. First, we
established HepG2 cell lines that constitutively expressed
RIPK2-shRNA (HepG2-shRIPK2-1/2-4) or control-shRNA
(HepG2-shC) (Figure 2C). The HepG2–shRIPK2-3 cell line,
which expresses the lowest levels of RIPK2, and the HepG2-
shC cell line were treated for 4 hours, with or without C12-
iE-DAP, before measurement by the NF-κB–driven luciferase
assay (Figure 2D and 2E). C12-iEDAP triggered NF-κB activa-
tion in HepG2-shC (Figure 2D) but not in HepG2–shRIPK2-3
(Figure 2E), indicating that RIPK2 plays an important role in
NF-κB activation induced through NOD1 triggering.
To assess the inﬂuence of HBeAg in that pathway, we mea-
sured NOD1-mediated NF-κB activity in HepG2-shC and
HepG2–shRIPK2-3 cell lines transiently transfected with
HBeAg-expressing plasmids. As shown in Figure 2D, HBeAg
expression in HepG2-shC abolished C12-iEDAP–induced NF-
κB activation.
HBeAg Interacts With RIPK2 and Colocalizes With RIPK2
RIPK2 mediates activation of transcription factors, such as
NF-κB, following its activation, which is initiated by mem-
brane-bound or intracytosolic receptors, such as TLR, NOD1,
and NOD2 [7, 13, 14]. Confocal microscopy analysis of cells
transfected with GFP-RIPK2 revealed subcellular localization
of RIPK2 (data not shown). To compare the localization of
RIPK2 with that of HBeAg, cells were cotransfected with
pGFP–human RIPK2 with pCXN2-HBeAg(+) or pCXN2-
HBeAg(−). After 48 hours, cells were stained withmousemono-
clonal anti-HBe antibody. Confocal microscopy suggested sub-
cellular colocalization of RIPK2 with HBeAg (Figure 2F).
Reinforcing this assumption, GFP-RIPK2 coimmunoprecipi-
tated with HBeAg (Figure 2G), while HBeAg coimmunopreci-
pitated with RIPK2 (Figure 2H) in transiently transfected cells
with RIPK2- and HBeAg-expressing plasmids.
DISCUSSION
In the present study, we have shown the expression of NOD1
and NOD1 ligand–induced NF-κB activation in HepG2 cells
and that RIPK2 plays an important role in NOD1 ligand–
induced NF-κB activation. NF-κB activation plays an essential
role in the production of inﬂammatory cytokines such as IL-6,
which HBeAg could suppress in hepatocytes [4]. We have also
shown that HBeAg inhibits RIPK2 expression and interacts
with RIPK2, which may represent 2 mechanisms through
which HBeAg blocks NOD1 ligand–induced NF-κB activa-
tion, thus contributing to the pathogenesis of chronic HBV
infection and establishing viral persistence, although further
studies including clinical situations might be needed.
HBeAg can be secreted by hepatocytes. Yet, it has been re-
ported that as much as 80% of the precore protein p22
remains localized to the cytoplasm rather than undergoing
further cleavage that allows its secretion as mature HBeAg
[15]. Our present study showed subcellular colocalization of
HBeAg with RIPK2 (Figure 2F). In addition to HBeAg protein
in cell culture medium, we observed similar inhibition of NF-
κB activation (data not shown).
Overall, we provided a novel molecular mechanism whereby
HBeAg modulates innate immune signal-transduction path-
ways through RIPK2. Elsewhere, it was also reported that
HBeAg impairs cytotoxic T-lymphocyte activity [2]. HBeAg
inhibits RIPK2 expression and interacts with RIPK2, decreas-
ing NF-κB activation and inﬂammatory cytokine production
in hepatocytes. Taken together, HBeAg could impair both
innate and adaptive immune responses to promote chronic
HBV infection.
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